Home > Health A – Z > Psoriatic Arthritis

Psoriatic Arthritis

A type of arthritis associated with psoriasis, a chronic skin disease that occurs when cells in the outer layer of the skin reproduce faster than normal.

PubMed Health Glossary
(Source: NIH - National Institute of Arthritis and Musculoskeletal and Skin Diseases)

About Psoriatic Arthritis

Psoriatic arthritis is a form of arthritis (joint inflammation) that can occur in people who have the skin disease psoriasis. Psoriasis is a common condition characterized by scaly red and white skin patches. Psoriatic arthritis can affect any joint in the body, including the spine.

Who is affected?

Anyone can be affected by psoriatic arthritis, but it is more common in Caucasians than African Americans or Asian Americans. It most commonly appears between the ages of 30 and 50, but it can also begin in childhood. According to the Centers for Disease Control and Prevention (CDC), 10 to 20 percent of people with psoriasis eventually develop psoriatic arthritis...Read more about Psoriatic Arthritis NIH - National Institute of Arthritis and Musculoskeletal and Skin Diseases

What works? Research summarized

Evidence reviews

Interventions for treating psoriatic arthritis

It has been estimated that arthritis occurs in 5‐7 % of those with psoriasis, which can cause substantial disability in some patients.

Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation

Etanercept, infliximab and adalimumab are licensed in the UK for the treatment of active and progressive psoriatic arthritis (PsA) in adults who have an inadequate response to standard treatment.

Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation

In active psoriatic arthritis, certolizumab and secukinumab had some incremental cost-effectiveness ratios of £20,000-30,000 per QALY, depending on psoriasis severity and the previous treatments used.

See all (87)

Summaries for consumers

Interventions for treating psoriatic arthritis

It has been estimated that arthritis occurs in 5‐7 % of those with psoriasis, which can cause substantial disability in some patients.

Psoriasis: Psoriatic arthritis

Psoriatic arthritis is a condition that leads to pain and stiffness in joints. It can be caused by psoriasis, but sometimes occurs in people who don't have any visible psoriasis-related skin changes. Various treatments can relieve the symptoms and prevent damage to the joints. It is estimated that 20% of people who have psoriasis also develop pain and inflammation in certain joints at some point. The joints start hurting and may feel stiff for a while, particularly in the morning. Movement often makes the stiffness disappear within half an hour. The affected joints may also become swollen, feel warm and sensitive to the touch. If the small joints between the vertebrae (spine bones) are inflamed, it might cause back pain. Psoriatic arthritis can occur in many joints of the body. It often affects the hands, feet, elbows, knees, neck or vertebrae. More than five joints typically become inflamed, including the joints at the end of the fingers and toes. These joints are especially prone to becoming deformed in severe cases. Tendons and tendon sheaths can also become inflamed. Most people who have psoriatic arthritis also have nail psoriasis. This can lead to small dents in the nails, which may become thicker, change color or start peeling off too. Nail psoriasis is difficult to treat and sometimes mistaken for a fungal nail infection.

Ixekizumab (Taltz) for the treatment of psoriasis: Ixekizumab (Taltz) as a first treatment with biological drugs for active psoriatic arthritis in adults

In 2018, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of ixekizumab (trade name: Taltz) when compared with the standard treatment of active psoriatic arthritis in adults. The manufacturer provided a study involving people who didn't benefit enough from previous treatment with conventional DMARDs or who didn't tolerate it well and who were able to have treatment with biological drugs for the first time. The data of 107 patients could be used in the analysis: Half of the patients received ixekizumab for 6 months, and the other half had already been having treatment with the available drug adalimumab for quite a while. Both drugs were injected under the skin using a pre-filled pen. The following results were found:

See all (21)

More about Psoriatic Arthritis

Photo of an adult

Other terms to know:
Arthritis, Plaque Psoriasis, Rheumatologist

Keep up with systematic reviews on Psoriatic Arthritis:

Create RSS

PubMed Health Blog...

read all...